Description

Simple

Clinical

Overview

Captodiame, also known as captodiamine, is an antihistamine which is used as a sedative and anxiolytic. It is a derivative of diphenhydramine. Captodiame has been suggested for use in preventing benzodiazepine withdrawal syndrome.

Pharmacology

Indication

Captodiame is indicated for the treatment of anxiety.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Renal.

Toxicity

-TDLo oral 17mg/kg (human) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX). PMID: 13535337.
-LD50 intraperitoneal 116mg/kg (mouse) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD. PMID: 13062090.
-LD50 intravenous 72mg/kg (mouse) BEHAVIORAL: ATAXIA. PMID: 14109651.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Captodiame
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The risk or severity of adverse effects can be increased when Captodiame is combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of adverse effects can be increased when Captodiame is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Captodiame is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Captodiame.
4-hydroxycoumarin
The risk or severity of adverse effects can be increased when Captodiame is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Captodiame.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Captodiame is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Captodiame.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Captodiame.
Acenocoumarol
The risk or severity of adverse effects can be increased when Captodiame is combined with Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Captodiame.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Captodiame.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Captodiame.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Captodiame.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Captodiame is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Captodiame may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Captodiame.
Adipiplon
The risk or severity of adverse effects can be increased when Adipiplon is combined with Captodiame.
Agomelatine
The risk or severity of adverse effects can be increased when Agomelatine is combined with Captodiame.
Ajulemic acid
The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Captodiame.
3 References
  1. 1 . Mercier-Guyon C, Chabannes JP, Saviuc P: The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. Curr Med Res Opin. 2004 Sep;20(9):1347-55.PubMed: 15383182
  2. 2 . PENTNEY BH, BROTHERWOOD RW: Captodiame in anxiety states in general practice. Practitioner. 1960 Aug;185:218-21.PubMed: 14431646
  3. 3 . Link Link